Hoffmann-La Roche

IMbrave150 | YO40245

NCT03434379

JCP037

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Atezolizumab + Bevacizumab

Treatment Arms

o Experimental: Atezolizumab + Bevacizumab

o Active Comparator: Sorafenib